local_hospital

Vasarhelyi Sarkanyfu Kft.

Address
lock Available on a paid plan

Cardiovascular Diseases

At Vasarhelyi Sarkanyfu Kft., cardiovascular disease research focuses on major conditions such as hypertension, atherosclerotic cardiovascular disease, and heart failure. These studies are designed to evaluate new ways to reduce cardiovascular risk, improve symptom control, and strengthen long-term outcomes for people with established heart and blood vessel disease.

  • Testing therapies aimed at lowering the risk of major cardiovascular events
  • Studying treatment options for uncontrolled hypertension and high cardiovascular risk
  • Evaluating medicines for heart failure in patients with limited treatment choices

This area reflects a strong interest in improving prevention and treatment for serious cardiovascular conditions through clinical research.

Immune System Diseases

The site is actively involved in immune system disease trials, especially for rheumatoid arthritis, psoriatic arthritis, and Sjögren’s syndrome. Research here aims to test new therapies, compare treatment effectiveness, and better understand how to control inflammation and disease activity in people living with chronic autoimmune disorders.

  • Evaluating new treatments for rheumatoid arthritis and treatment-resistant disease
  • Comparing therapies for active psoriatic arthritis and related joint symptoms
  • Studying options for Sjögren’s syndrome, including symptom relief and systemic disease control

These trials highlight a broad focus on autoimmune disease management and the search for more effective, better-tolerated therapies.

Musculoskeletal Diseases

Clinical research at this Hungarian site includes important work in musculoskeletal diseases, with a particular emphasis on rheumatoid arthritis and psoriatic arthritis. The studies are generally focused on improving joint function, reducing pain and inflammation, and assessing how well emerging treatments work in everyday clinical care.

  • Assessing new and existing therapies for inflammatory joint disease
  • Comparing treatment effectiveness in moderate to severe arthritis
  • Exploring longer-term safety and symptom control in chronic musculoskeletal conditions

This research supports better care for people affected by persistent joint and connective tissue disorders.

Skin and Connective Tissue Diseases

The site also participates in trials for skin and connective tissue diseases, particularly plaque psoriasis and psoriatic arthritis. These studies are aimed at testing new treatment approaches that may improve skin symptoms, reduce inflammatory activity, and help patients achieve better overall disease control.

  • Evaluating therapies for moderate to severe plaque psoriasis
  • Studying treatments that address both skin and joint involvement in psoriatic disease
  • Measuring how well investigational options reduce disease activity and improve patient outcomes

This area shows a clear focus on psoriatic disease and related inflammatory skin conditions.

Immune System Phenomena

Research into immune system phenomena at Vasarhelyi Sarkanyfu Kft. centers on how immune-driven inflammation affects different diseases, including rheumatoid arthritis and Sjögren’s syndrome. The trials are intended to better understand immune activity and to assess whether new therapies can more effectively control the underlying disease process.

  • Investigating immune-targeted treatments for autoimmune inflammation
  • Assessing changes in disease activity linked to immune modulation
  • Exploring ways to improve control of chronic immune-mediated conditions

This research strengthens knowledge of immune regulation in chronic inflammatory disease and supports development of more precise therapies.

Immune System Processes

The site’s work in immune system processes includes studies that look at how inflammatory pathways contribute to diseases such as psoriatic arthritis, rheumatoid arthritis, and Sjögren’s syndrome. The purpose of these trials is to evaluate whether targeted treatments can improve disease control, reduce symptoms, and offer more durable benefits over time.

  • Testing therapies that act on inflammatory pathways
  • Evaluating symptom improvement in chronic autoimmune conditions
  • Supporting development of more effective long-term treatment strategies

This field of research reflects an ongoing effort to better understand and treat immune-mediated disease processes.

Site Overview

assignment
22
connected trials
corporate_fare
13
sponsors
science
25
IMPs

Activity Indicator

Last 6 months

2
Trials started
0% vs previous period.
2
Trials started 6–12 months ago
22
Total trials linked
Highly Active
trending_flatStable0%
1
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 6 therapeutic areas and 15 of 25 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
10
Sponsors (total)
13
Active sponsors
7

Sponsor Network

Top 7 by active trials.

lock +6 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +4 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 332 other sites in Hungary

description
Trial volume
22
Outperforms 82% of sites
public
Therapeutic diversity
6areas
Outperforms 86% of sites
groups
Sponsor diversity
13sponsors
Outperforms 82% of sites

Therapeutic Area Benchmark — Hungary

Select a therapeutic area to compare against other sites in Hungary.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Hungary

Market Share

Country: Hungary

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Vasarhelyi Sarkanyfu Kft.

lock Showing 1 of 22 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-88545223 in Participants with Active Psoriatic ArthritisJanssen Cilag InternationalPhase IIRecruitingMar 2026

IMP list

lock Showing 1 of 25 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Dazodalibep3Unknown2024-06-072025-05-16

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.